Comprehensive new guidelines for screening, targeted testing, and treating latent tuberculosis infection (LTBI) in children and adolescents are presented. The recent epidemiology of TB and data on risk factors for LTBI are reviewed. The evidence-based recommendations provided emphasize the paradigm that children and adolescents should be screened for risk factors by using a risk-factor questionnaire for TB and LTBI and tested with the tuberculin skin test only if ≥1 risk factor is present. The use of administrative or mandated tuberculin skin tests for entry to day care, school, or summer camp is strongly discouraged. Treatment regimens, suggestions to improve adherence, and methods to monitor toxicities are summarized. Children and adolescents with LTBI represent the future reservoir for cases of TB. Thus, detecting and treating LTBI in children and adolescents will contribute to the elimination of TB in the United States.
Skip Nav Destination
Article navigation
October 2004
Supplement Articles|
October 01 2004
Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents
Pediatric Tuberculosis Collaborative Group
Pediatric Tuberculosis Collaborative Group
Search for other works by this author on:
Address correspondence to Lisa Saiman, MD, MPH, Division of Infectious Diseases, Department of Pediatrics, Columbia University, College of Physicians and Surgeons, 650 W 168th St, PH 4 West Room 470, New York, NY 10032. E-mail: [email protected] Reprint requests to Paul Colson, PhD, Charles P. Felton National Tuberculosis Center at Harlem Hospital, Kountz, 6th Floor, 15 W 136th St, New York, NY 10037. E-mail: [email protected]
Pediatrics (2004) 114 (Supplement_4): 1175–1201.
Article history
Accepted:
June 29 2004
Citation
Pediatric Tuberculosis Collaborative Group; Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents. Pediatrics October 2004; 114 (Supplement_4): 1175–1201. 10.1542/peds.2004-0809
Download citation file:
Sign in
Don't already have an account? Register
Purchased this content as a guest? Enter your email address to restore access.
Please enter valid email address.
Pay-Per-View Access
$35.00
Comments